Clinical trial registry record

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 10, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01254513
Last registry update
June 10, 2021
Status
Completed
Phase
Phase 2
Sponsor
UNICANCER
Enrollment
66
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
66
Population
MALE · 75 Years
Duration
2010-12-09 to 2017-04-27
Intervention
Docetaxel every 3 weeks + Prednisone; Docetaxel weekly+ Prednisone
Comparator
Not reported
Outcomes measured
Feasibility of 2 different protocols of Docetaxel chemotherapy — Up to 18 weeks (6 cycles of chemotherapy); Overall Survival — From randomization until death for any cause or last follow-up news (censored data); Geriatric evaluation — At baseline, D1 of Cycle 1 and Cycle 4, at the end of treatment and at follow-up visits; Number of patients with Adverse Events — At baseline, D1 of each cycle , at the end of treatment and at the follow-up v…; Quality of Life — At baseline, D1 of the Cycle 4, at the end of the treatment and at the follow-up visits; Vital signs measurement — At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits; Prostate-specific antigen (PSA) measurements — At baseline, D1 of each cycle , at the end of treatment and at the follo…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON